As of 2025-04-19, the EV/EBITDA ratio of Travere Therapeutics Inc (TVTX) is -7.62. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. TVTX's latest enterprise value is 1,644.90 mil USD. TVTX's TTM EBITDA according to its financial statements is -215.95 mil USD. Dividing these 2 quantities gives us the above TVTX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 10.9x | 9.7x |
| Forward P/E multiples | 13.3x - 19.9x | 16.6x |
| Fair Price | (35.92) - (30.17) | (35.66) |
| Upside | -340.7% - -302.2% | -339.0% |
| Date | EV/EBITDA |
| 2025-04-11 | -7.44 |
| 2025-04-10 | -7.03 |
| 2025-04-09 | -7.38 |
| 2025-04-08 | -7.30 |
| 2025-04-07 | -7.72 |
| 2025-04-04 | -7.65 |
| 2025-04-03 | -8.29 |
| 2025-04-02 | -8.86 |
| 2025-04-01 | -8.65 |
| 2025-03-31 | -8.85 |
| 2025-03-28 | -9.57 |
| 2025-03-27 | -9.86 |
| 2025-03-26 | -10.03 |
| 2025-03-25 | -10.12 |
| 2025-03-24 | -10.24 |
| 2025-03-21 | -9.92 |
| 2025-03-20 | -10.05 |
| 2025-03-19 | -9.99 |
| 2025-03-18 | -9.64 |
| 2025-03-17 | -10.06 |
| 2025-03-14 | -9.59 |
| 2025-03-13 | -9.35 |
| 2025-03-12 | -9.41 |
| 2025-03-11 | -8.93 |
| 2025-03-10 | -8.83 |
| 2025-03-07 | -8.92 |
| 2025-03-06 | -9.27 |
| 2025-03-05 | -9.46 |
| 2025-03-04 | -9.58 |
| 2025-03-03 | -9.62 |
| 2025-02-28 | -10.28 |
| 2025-02-27 | -9.97 |
| 2025-02-26 | -10.13 |
| 2025-02-25 | -9.97 |
| 2025-02-24 | -10.21 |
| 2025-02-21 | -10.52 |
| 2025-02-20 | -11.18 |
| 2025-02-19 | -11.07 |
| 2025-02-18 | -10.80 |
| 2025-02-14 | -10.90 |
| 2025-02-13 | -11.23 |
| 2025-02-12 | -11.02 |
| 2025-02-11 | -11.25 |
| 2025-02-10 | -10.16 |
| 2025-02-07 | -10.42 |
| 2025-02-06 | -10.47 |
| 2025-02-05 | -10.20 |
| 2025-02-04 | -10.16 |
| 2025-02-03 | -9.80 |
| 2025-01-31 | -9.89 |